Skip to main content

Latest SEC Filings — Page 82

Most recent SEC EDGAR filings across all covered tickers, sorted chronologically. Wiseek AI reads each filing and scores it 1–10 for market-moving potential; click through for full analysis.

How Wiseek curates this list

Every filing on this page is sourced directly from SEC EDGAR, the U.S. Securities and Exchange Commission's public filings system. Wiseek processes 8-K, 10-K, 10-Q, Form 4, Form 144, DEF 14A, Schedule 13D/A and related disclosures filed by U.S.-listed companies. The original filing is always linked from each article so readers can verify the source document directly.

How filings get scored

Each filing runs through Wiseek's importance scorer, which weights filing type, deal magnitude, insider participation, material-event flags (going-concern, restatements, executive transitions, M&A) and historical market-reaction patterns. Filings scoring below 7 on the 1–10 scale are filtered out at the database query so this list stays focused on market-moving disclosures. See our methodology for the full rubric.

Editorial standards

Wiseek does not edit the underlying SEC filing. Plain-English summaries and key-event extractions are generated from the verified source text and clearly attributed as AI-generated. Wiseek does not provide investment advice — see our editorial policy for full standards on accuracy, source disclosure, and corrections.

Wave Life Sciences Reports Strong Q1 Financials with 4x Revenue Growth and Advances Key Pipeline Programs
ProForm 10-QWVE · Form 10-Q · 5d ago
Schrodinger Seeks Shareholder Approval for 3 Million Share Increase to Equity Incentive Plan
Form DEF 14ASDGR · Form DEF 14A · 5d ago
Cardiol Therapeutics Expands Phase III MAVERIC Trial Network, Reaches 75% Patient Enrollment
ProForm 6-KCRDL · Form 6-K · 5d ago
Hut 8 Subsidiary Prices $3.25 Billion Senior Secured Notes for 245MW Data Center Project
ProForm 8-KHUT · Form 8-K · 5d ago
Commvault Exceeds Q4 Revenue Estimates, Reports Strong SaaS Growth, and Recommits $250M Share Repurchase Program
ProForm 8-KCVLT · Form 8-K · 5d ago
20/20 Biolabs Amends Warrants, Reducing Exercise Price to $2.25 for Key Investor
ProForm 8-KAIDX · Form 8-K · 5d ago
Hillman Solutions Reports Wider Q1 Net Loss, Increased Cash Burn, Announces Two Acquisitions
Form 10-QHLMN · Form 10-Q · 5d ago
Wave Life Sciences Reports Strong Q1 Results, Extends Cash Runway, and Advances Key Pipeline Programs
ProForm 8-KWVE · Form 8-K · 5d ago
Rocket Pharmaceuticals Secures $180M Non-Dilutive Capital from PRV Sale, Extends Cash Runway
ProForm 8-KRCKT · Form 8-K · 5d ago
Kiniksa Pharmaceuticals Reports Strong Q1 2026 Results, Raises ARCALYST Revenue Guidance
ProForm 8-KKNSA · Form 8-K · 5d ago
CEO's 'Actually Paid' Compensation Turns Negative in 2025 Amidst Worsening Financial Performance
ProForm DEF 14ARNAC · Form DEF 14A · 5d ago
AstraZeneca's Breztri Approved by US FDA for Asthma, First Triple Therapy for Patients 12+
ProForm 6-KAZN · Form 6-K · 5d ago
PMGC Subsidiary Files New Patent for Muscle Preservation Drug in Humans
Form 8-KELAB · Form 8-K · 5d ago
Cabaletta Bio Seeks Shareholder Approval to Double Authorized Stock Amidst Going Concern Warning
ProForm DEF 14ACABA · Form DEF 14A · 5d ago
Neurocrine Biosciences Tender Offer for Soleno Therapeutics Clears HSR Regulatory Hurdle
ProForm SC TO-T/ASLNO · Form SC TO-T/A · 5d ago
HSR Waiting Period Expires for Neurocrine's Acquisition of Soleno Therapeutics
ProForm SC 14D9/ASLNO · Form SC 14D9/A · 5d ago
WEX Defends Board and Strategy, Alleges Conflicts of Interest for Activist Nominee in Proxy Battle
ProForm DEFA14AWEX · Form DEFA14A · 5d ago
Soluna Holdings Partners with Sazmining for 3 MW Bitcoin Mining Deployment at Project Dorothy 1B
ProForm 8-KSLNH · Form 8-K · 5d ago
Watsco Reports Q1 Results, Boosts Dividend 10%, and Announces $230M Acquisition
ProForm 8-KWSO · Form 8-K · 5d ago
Soligenix's Lead Phase 3 Trial for HyBryte™ Fails for Futility, Raising Significant Going Concern Risks
ProForm 8-KSNGX · Form 8-K · 5d ago
General Motors Beats Q1 Adjusted EPS, Raises Full-Year Adjusted Guidance on Favorable Tariff Ruling
ProForm 8-KGM · Form 8-K · 5d ago
Massive Resale Registration Filed for 24.87M Shares, Signaling Over 1800% Potential Dilution
ProForm S-3SNSE · Form S-3 · 5d ago
GSK's Bepirovirsen Receives US FDA Priority Review & Breakthrough Therapy Designation for Chronic Hepatitis B
ProForm 6-KGSK · Form 6-K · 5d ago
Waterdrop Reports Strong 2025 Financials with 43.5% Revenue Growth and Significant AI Expansion
ProForm 20-FWDH · Form 20-F · 5d ago
Zai Lab Seeks Shareholder Approval for 10% Share Issuance & Repurchase Mandates, Details Related-Party Licensing Deal
Form DEF 14AZLAB · Form DEF 14A · 5d ago
BioLineRx Doses First Patient in Phase 1/2a Glioblastoma Study for Novel GLIX1 Drug
ProForm 6-KBLRX · Form 6-K · 5d ago
reAlpha Tech Reports Worsening Q1 Loss and Cash Decline, Concurrent 10-Q Raises Going Concern Doubt
ProForm 8-KAIRE · Form 8-K · 5d ago
S&P Global Reports Strong Q1 Results, Beats EPS Estimates, Maintains Full-Year Guidance, and Repurchases $1 Billion in Shares
ProForm 8-KSPGI · Form 8-K · 5d ago
AvalonBay Reports Mixed Q1 Results, Updates Full-Year EPS Outlook, Continues Share Repurchases
Form 8-KAVB · Form 8-K · 5d ago
Genprex Reports Positive Preclinical Data for Diabetes Gene Therapy GPX-002
ProForm 8-KGNPX · Form 8-K · 5d ago